The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
After being informed about the study and potential risks, patients will be screened to determine eligibility for the study and consented. Patients who meet eligibility requirements will be immunized with PCV 20. HIV-infected adults will be tested prior to and after vaccination by blood, nasal filter paper, and stool samples to characterize mucosal and systemic antibody responses . HIV-uninfected control adults will be tested at vaccination and post vaccination to characterize mucosal and systemic antibody responses .
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Enrollment
100
One time administration of prevnar-13 vaccine
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, United States
Determine pneumococcal specific IgG levels in BAL (BronchoAlveolar Lavage) fluid and NPF (Nasopharyngeal Fluid)
Determine pneumococcal specific IgG levels in BAL fluid and NPF and to standardize the results we will compare it to the total levels in the BAL/NPF fluid collected at all timepoints
Time frame: A change from baseline, measured at pre-vaccination, and 1 month post vaccine
Determine pneumococcal specific IgG levels in serum
Determine pneumococcal specific IgG levels in serum 1 month post vaccination response criteria must meet \>2-fold rise with a post-vaccination level \>1000 ng/ml for \> 7 of the 12 serotypes
Time frame: A change from baseline, measured at pre-vaccination, and 1 month post vaccine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.